PathAI, a company that provides AI-powered technology for advancing pathology research, announced on Tuesday that it has named Pathologist and executive leader Eric Walk, MD, FCAP, as its new chief medical officer.
In the new role, Dr Walk is to manage Clinical, Regulatory, Medical Affairs and Pathology teams.
Dr Walk has held the position of chief medical & scientific officer and SVP of Medical and Scientific Affairs at Roche Tissue Diagnostics (Ventana Medical Systems). He was a member of the Roche Medical Leadership Team establishing the global medical strategy for the Diagnostics division. He has worked at Novartis Oncology in Translational Medicine and Early Clinical Development.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA